Cost Analysis of PSMA-PET in the PROSPET-BX Trial
To the best of our knowledge, this is the first cost analysis study to compare different strategies incorporating PSMA-PET in the re-biopsy setting, demonstrating that the combined "mpMRI or PSMA-PET" pathway is the most cost-effective diagnostic pathway for csPCa detection.
Authors
- Luca Disconzi (ORCID: https://orcid.org/0009-0001-0784-7090)
- Elena Vanni (ORCID: https://orcid.org/0000-0003-4928-3550)
- Alessandro Santandrea (ORCID: https://orcid.org/0000-0002-0093-2970)
- Alberto Saita (ORCID: https://orcid.org/0000-0003-0000-5517)
- Egesta Lopci
- Cesare Saitta
- Giovanni Lughezzani
- Nicolò Buffi
- Vittorio Fasulo
- Massimo Lazzeri
Institutions
- Humanitas University (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Cancers
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3390/cancers18050806
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00